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A B S T R A C T
Clinical decision-making skills are recognized as a central component of professional competency but are under-
developed in pharmacy compared to other health professions. There is an urgent need for a comprehensive
understanding of how pharmacists can best develop and use therapeutic decision-making skills in clinical
practice. The aims of this commentary are to define clinical decision-making in pharmacy practice, and to
present a model for clinical decision-making that aligns with a philosophical framework for pharmacy practice.
The model has utility in education programs for pharmacists and provides a framework for understanding pa-
tient-facing clinical services in practice.
1. Introduction
In the seminal paper by Donald Brodie, “Drug-use control: keystone
to pharmaceutical service”,1 it was argued that pharmacy lacked a
crucial ingredient to unify and define the profession, which he termed a
‘body of practice’. He noted that the prevailing practice model focused
predominantly on the manufacture and sale of medicines. Dispensing,
he argued, while important, was not a role that would allow pharma-
cists to fully extend their professional scope. Brodie proposed the
concept of ‘drug-use control’, essentially a patient-centered clinical role,
as a core function for the pharmacy profession across all practice set-
tings.1
The sentiment that pharmacy should fully embrace a patient-facing
clinical role as a central component of practice has been repeated
several times over the past few decades. The findings of the Millis
Commission,2,3 and the Nuffeild Report4 stressed that pharmacy should
be foremost a clinical profession. However, it was not until 1989 that a
coherent ‘body of practice’ was proposed with the publication of Hepler
and Strands seminal work on pharmaceutical care.5,6 Pharmaceutical
care was defined as “the responsible provision of drug therapy for the
purpose of achieving definite outcomes that improve a patient's quality
of life”.5 Hepler and Strand suggested that the central purpose of the
pharmacy profession should be to ensure the safe and effective use of
medicines. Pharmaceutical care was seen as a professional orientation
that would facilitate the transition from a traditional focus on dispen-
sing and manufacturing to a practice model focused on clinical services.
In the decades since the introduction of pharmaceutical care, there
has been a gradual maturation of pharmacy as a clinical profession. This
change has been driven, in part, by the efforts of government bodies,
educators, and professional organizations who have raised the issue
that pharmacists are under-utilized in modern health care (see for ex-
ample7-11). The end result is that pharmacists in all practice settings are
now increasingly expected to provide a variety of clinical services in-
cluding, for example, vaccination, anticoagulant monitoring, medicines
review services, and prescribing. In many cases, pharmacists are ex-
pected to be active members of the health care team with direct re-
sponsibility for designing and implementing therapeutic treatment
plans. Signals from government bodies in several jurisdictions, in-
cluding the United Kingdom,10 United States,12 New Zealand,13 and,
Canada,7 suggest that clinical pharmacy services are expected to grow
in the coming years and that practice will continue to expand into new
settings. It would appear that, 50 years on, Brodie's vision for a patient-
facing ‘body of practice’ for the pharmacy profession, might finally be
close to realization.
The central argument presented in this paper is that, despite pro-
mising advances in clinical pharmacy practice over the past several
years, we are still falling short of achieving Brodie's vision of a unified
professional ‘body of practice’. We contend that clinical decision-
making remains a critical missing ingredient that will allow pharma-
cists across practice settings to expand their scope of practice beyond
the supply of medicines. While clinical decision-making skills related to
diagnostic decisions are well-recognized as a fundamental component
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of practice in medicine, the decisions-making skills required for ther-
apeutic decisions remain under-developed.14
The aims of this commentary are to; 1) present a definition for
clinical decision-making that will apply across pharmacy practice set-
tings 2) to propose a model for clinical decision-making aligned with a
philosophical framework for pharmacy practice, and, 3) to explore the
implications for pharmacy practice and education in the 21st century.
Note that it is not the intention of this paper to review the vast litera-
ture on clinical decision-making and clinical reasoning in the medical
profession.
2. What do we mean by ‘clinical decision-making’?
There is no widely accepted definition of clinical decision-making
nor any consistent use of terminology. While we do not intend to review
the language used by other health professions, we observe that many
terms have been used more-or-less interchangeably to describe similar
phenomena. These include ‘problem solving’, ‘critical thinking’ ‘clinical
reasoning’, ‘diagnostic reasoning’, ‘clinical judgment’, and ‘clinical de-
cision-making’.15-20 In medicine, it is common to refer to the broad
decision-making process around diagnosis as ‘clinical reasoning’, while
‘management reasoning’ has been used to describe decision-making
around drug therapy.14 The latter is analogous to our definition for
pharmacy (below). ‘Therapeutic decision-making’ in the medical lit-
erature, confusingly, generally refers to the computational analysis of
decision trees using mathematical models.21,22 We will not discuss the
latter here. Note that we do not believe that the terminology used by
medicine is part of a consistent language but simply reflects the prag-
matic development of terms. In this work, and for clarity, we will use
‘clinical decision-making’ to refer to the whole set of cognitive skills
required to reach a decision about drug therapy.
3. Current models for clinical decision-making in pharmacy
practice
Clinical decision-making has not been explored in any detail in the
pharmacy literature compared to other health professions. Most pub-
lished models are focused primarily on defining the practical steps that
might be required to conduct pharmaceutical care services. While the
models suggested by Brodie et al.,23 Strand et al.,24 Hepler and Strand6
and Sexton et al.25 provide a useful ‘how to’ guide for the pharma-
ceutical care process, the specific skills and cognitive processes required
for decision-making are not addressed. The overarching impression is
that clinical decision-making is tacit and will therefore either be in-
nately obvious or will only be acquired with practice experience and
mentoring.
Bryant26 explored the clinical decision-making process by posi-
tioning a model for the pharmaceutical care process proposed by Hepler
and Strand model within the framework of evidence-based medicine.
The author proposed that drug therapy decisions are driven by the
quality of the evidence-base, and require ‘logical’ reasoning and clinical
judgment skills.26 By teasing apart the components of clinical decision-
making, Bryant provides a framework that could be translated into a set
of teachable skills. For example, evidence about drug treatments would
require critical appraisal skills while ‘logical’ reasoning might require
critical thinking skills.26 According to Bryant, clinical judgment is re-
quired where there is no evidence-base to aid decision-making and
therefore remains the domain of the experienced practitioner.
Other authors have presented the Hepler and Strand model in var-
ious forms, although the basic structure remains largely intact (see for
example27,28). Some specific skills that are important for the decision-
making process have also been explored including critical thinking and
problem-solving skills,29-33 information gathering,34 clinical reasoning
skills,35,36 and decision-making for differential diagnosis in the com-
munity pharmacy setting.37-39 While this research is encouraging, there
is no comprehensive model that defines the processes and skills
required for pharmacists to effectively make independent patient-cen-
tered decisions about treatment plans when conducting clinical ser-
vices.
4. A definition of clinical decision-making for pharmacy practice
Clinical decision-making in pharmacy practice can be con-
ceptualized as a series of cognitive processes and skills that allow
pharmacists to make patient-centered, therapeutic decisions. We intend
for this definition to be applicable across practice settings, in any en-
vironment where a pharmacist would be expected to conduct patient-
centered clinical services whether in community, primary care, or
hospital practice.
It is important to note that our proposed definition of clinical de-
cision-making differs in some important aspects from that used in
medicine. In medical practice, clinical decision-making is used syno-
nymously with the term ‘clinical reasoning’ and it is characterized as
the thinking process medical practitioners use “to sort through a cluster
of features presented by a patient and accurately assign a diagnostic
label …”.40 Clinical decision-making in medicine emphasizes diagnosis
rather than therapeutics.41 Pharmacists, on the other hand, usually
interact with patients and health care teams in a setting where the di-
agnostic label has been assigned but where therapeutic options may not
yet be optimal.
5. A revised model for clinical decision-making in pharmacy
practice and education
A model for the clinical decision-making process in pharmacy
practice has been introduced by the authors previously.42 This model
has been refined further and is presented in Fig. 1. It builds on the work
of Hepler and Strand,6 Sexton et al.,25 and Bryant et al.,26 but differs in
that it focuses on the cognitive processes required for decision-making.
The cognitive processes are represented as a 4-stage cycle and the tasks
that enable decision-making are defined within each stage. These tasks
are inherently teachable as a series of skills, so the model can be
adapted into an education program or personal practice (see for ex-
amples43,44). Finally, to highlight the patient-centered intentions of the
model the patient is the central axis around which all decision-making
activity occurs.
The tasks embedded in each cognitive process in the model are
described in detail below.
1. Information gathering. Information gathering is a multifaceted
stage and will include a diverse range of tasks including, but not
limited to; identifying the need for a decision, an assessment of la-
boratory results, the identification of drug-related problems, the
initial delineation of treatment and patient-centered goals, patient
assessment (physical and psycho-social), a review of relevant lit-
erature related to therapeutic entities, and a consideration of patient
Fig. 1. A general model for the clinical decision-making process in pharmacy.
The dashed line around the decision component indicates that this is the final
step in process and will be enacted with the patient.
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factors that may impact drug therapies (e.g. risk of adverse effects).
Unlike the Hepler and Strand model, information gathering is in-
itiated by a signal indicting that a decision is required. This differ-
ence is a subtle point, but information gathering, as envisioned here,
is related specifically to the problem so it will occur after the
pharmacist has identified the need for a decision. This might occur
while conducting medicines review services, during a patient con-
sultation, while monitoring the outcomes of a previous decision, or
from an external source, e.g. a referral. In some cases, the signal that
initiates the decision-making process may be driven by the patient,
and in other cases, may occur in the absence of direct patient con-
tact. The types of signals that initiate the decision-making process
are diverse, and will inevitably extend beyond ‘drug-related pro-
blems’ as defined in pharmaceutical care. The information gathering
stage does not necessarily need to be contextualized to an individual
patient. A pharmacist could, for example, research and answer a
drug information query without access to detailed patient in-
formation. Likewise, a clinical check of a prescription that requires
clarification with the prescriber (as may occur if an inappropriate
dose is identified) may only superficially extend beyond information
gathering in the absence of patient level data.
2. Clinical reasoning. From a practical perspective, the clinical rea-
soning stage requires the pharmacist to appraise the information
gathered and to contextualize this specifically to the goals of the
patient. The aim of this stage is to curate the information gathered
and synthesize a viable set of options in the context of the patient's
goals. We consider that clinical reasoning is much more than the
collation of options from the evidence-base or from published
treatment guidelines. It requires the pharmacist to use critical
thinking skills to appraise the information gathered and to ensure
that the information is robust so it will suit the needs of the patient.
The clinical reasoning step will provide the basic components to
enable clinical judgement.
3. Clinical Judgment. While previous authors have suggested that
clinical judgement is only required when the evidence-base to sup-
port a treatment decision is lacking,26 we propose that it is an in-
tegral component of all decision-making activities (whether clinical
or not). Clinical judgement can be understood as the process of
weighing-up the options available, and prioritizing them on the
basis of their impact. The impact of a decision will extend beyond
the treatment outcomes for the patient's health and may also include
financial considerations, social implications, effects on the patient's
family, or how the patient interacts with other health services. In all
cases, judgement involves a benefit-risk assessment. We note if there
were no benefits from an intervention or no risks (health, financial
or otherwise) then the judgement is absolute. Otherwise, the as-
sessment carries a trade-off between the benefits and risks of any
intervention. The clinical judgement step is one based on ambiguity
and uncertainty and is a foundational component in the clinical
decision-making process.
4. Decision. Making a decision is the final stage in the process and it is
made in partnership with the patient. In the judgement step, the
practitioner will assign a weighting to each reasoned option.
Importantly, this is the transition from a set of weighted options to a
patient-centered decision. In this way, the decision step culminates a
judgement with an action such that the patient is part of the inter-
pretation of the judgement. In summary, the decision stage has at
least two embedded tasks: (i) a patient-centered consideration of the
pertinent judgements through an open and supportive communica-
tion framework and (ii) the enactment of the decision. In the en-
actment of the decision, the consultative recipient may either be the
patient or another health professional.
We acknowledge that the clinical decision-making process in health
care is inherently complex and requires consideration of several factors
simultaneously such as the patient goals, the evidence-based for
different treatments, and social expectations. In addition, we propose
that decision-making in pharmacy practice, with a primary focus on
therapeutic decisions, will differ fundamentally from medicine, where
the emphasis is on deductive reasoning to arrive at a diagnosis.
6. Aligning the CDM model with a philosophical framework for
pharmacy practice
Prior to developing the clinical decision-making model further, we
introduce a previously published philosophical framework for phar-
macy practice.42 The current work is intended to build on this work by
aligning the framework with the decision-making model presented
above. The use of bioethical principles is intended to provide a philo-
sophical underpinning for pharmacy practice that will help delineate
different approaches to clinical decision-making and which will have
important implications for professional identity. We theorize that
clinical decision-making will differ depending on the bioethical or-
ientation of the service being delivered.
We have previously proposed that the professional services pro-
vided by pharmacists can be aligned with the foundational principles of
bioethics, specifically, non-maleficence (to avoid harm) and benefi-
cence (to do good).42 For instance, a pharmacy practitioner providing
services that are primarily non-maleficent will make decisions designed
to mitigate risk.
A non-maleficent pharmacy service may be primarily drug-focused
and could occur in a setting with limited access to patient information.
An example would be providing a clinical check for drug interactions at
the time of dispensing. In this case, the pharmacist is identifying a
signal of a potential harm, is acting on this via the decision process, and
will follow up with the practitioner or patient. In this example, the
pharmacist did not instigate the care process (i.e. the diagnosis and
prescription) but rather provides support to the process. Non-maleficent
services could also be a primary component of a patient-centered
clinical role for the purposes of reducing iatrogenic burden, e.g. iden-
tifying medicines that carry risk with limited anticipated benefit in a de-
prescribing service.
A pharmacy practitioner providing beneficent services will make
decisions that are oriented towards creating benefit. We have identified
three main types of services with a beneficent orientation; primary
beneficence, secondary beneficence, and co-beneficence.42
A primary beneficent service is one in which the pharmacist is the
instigator of a treatment or intervention that has not previously been
considered by another healthcare professional. A pharmacist providing
primary beneficent services will identify the need for a decision and
continue through the process to enact a decision in an independent and
autonomous manner. Note here, independent is used to indicate that
the clinical decision-making process is internal to the practitioner and
not consultative – this does not imply that the practitioner does not
work in a collaborative healthcare setting. A primary beneficent service
could include a pharmacist vaccinating a patient.
A secondary beneficent service is one where a pharmacist provides
support to another (primary beneficent) practitioner. To this end, the
pharmacist (the secondary beneficent practitioner) is involved in the
overall decision-making process up to and including the clinical jud-
gement step of the other healthcare practitioner (primary beneficent
practitioner) who is the person responsible for arriving at and enacting
the decision. A secondary beneficent service may also involve a phar-
macist acting to influence the reasoning, judgements, or decisions that
were initiated by a primary beneficent practitioner to improve patient
outcomes. An example of a secondary beneficent service is medicines
review that aims to optimize the therapeutic choices of a prescribing
physician.
A co-beneficent service requires the pharmacist to work collabora-
tively with another healthcare practitioner and to share the responsi-
bility for a decision that is made and enacted together. Providing a co-
beneficent service may involve asynchronous completion of the
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decision-making cycle by the two practitioners in order to complete
different aspects of the process. In practice, a co-beneficent service
might involve shared prescribing roles between a pharmacist and a
medical practitioner in a primary care setting. In this setting the phy-
sician may assign the diagnostic label and identify the overall ther-
apeutic approach that aligns with their prognostic reasoning and the
pharmacist may identify and enact the particular therapeutic inter-
vention. Separation of the roles of diagnostician and prescriber has
potential significant advantages.
We acknowledge that non-maleficent services and beneficent ser-
vices are not mutually exclusive. The professional activities of a phar-
macist may have both non-maleficent and beneficent components, ei-
ther within the same role or in different roles that they may perform.
For instance, the clinical checking of prescriptions (in the absence of
information about diagnosis and medical goals) will require pre-
dominately a non-maleficent approach where the pharmacist may pri-
marily see their role to reduce harm. A prescribing pharmacist, who
may be designing and implementing treatment plans, will adopt a
beneficent orientation, which will enhance well-being within an ac-
ceptable harm risk. It may be that a pharmacist follows both compo-
nents, e.g. a prescribing pharmacist who is involved in de-prescribing.
Here the orientation of the role is non-maleficent, but the practice
setting of prescribing (in this case potentially stopping a medicine)
holds a natural beneficent component. In all pharmacy services there
will be a dominant philosophical approach that can be identified. The
difference in clinical decision-making therefore lies in the underpinning
philosophical approach which dominates in any given service. This
distinction provides a useful means of understanding professional
identify in pharmacy.
7. An expanded model for clinical decision-making
The decision-making model can been expanded to show non-mal-
eficent (Fig. 2), secondary beneficent (Fig. 3), and, co-beneficent
(Fig. 4), services and how they interact with the primary beneficent
decision-maker. These represent the decision-making cycles associated
with services provided by pharmacists in different practice settings. In
the case of a non-maleficent service, the pharmacist's clinical decision-
making process interrupts that of the primary beneficent practitioner
(Fig. 2). The decision of the pharmacist may require contact with the
prescriber or patient as part of the decision step.
Figs. 3 and 4 show the complex clinical decision-making interac-
tions that may occur between different beneficent practitioners. Unlike
some non-maleficent practice settings, beneficent practice is always
patient-centered, and requires the pharmacist to have access to ap-
propriate patient information, such as clinical conditions and labora-
tory investigations, to aid in the decision-making process. These ser-
vices would require pharmacists to move beyond clinical checking of
prescriptions to providing services where they are required to take a
lead role in therapeutic decisions.
In all settings, the clinical decision-making steps remain equally
important and clearly delineated. However, it is apparent that the skills
and cognitive processes that underpin each of the tasks will differ
dramatically between the four orientations to practice. It is also sus-
pected, but not previously explored, that moving from one orientation
(e.g. non-maleficent) to another (e.g. co-beneficent) requires a non-
trivial shift in skills and cognition, and importantly, the professional
identity of the practitioner.
8. Implications for pharmacy practice and education
Pharmaceutical care, as a body of practice, has a strong non-mal-
eficent tone. The motivation for Hepler and Strand's pharmaceutical
care model was the pressing clinical need to reduce drug-related mor-
bidity and mortality.5 They suggested that pharmacy's primary mandate
is “… to help the patient obtain the best possible drug therapy and
especially to protect the patient from harm”.5 Pharmacists were tasked
with resolving ‘drug-related problems’ such as identifying medicines
that were missing or doses that were sub-therapeutic or toxic.5,6 While
the design and implementation of treatment plans was also stressed as
an important function for pharmacists, Hepler and Strand did not
provide guidance about how the necessary therapeutic decisions would
be reached or what skills would be required to provide such services.
Other authors have suggested that the definition of pharmaceutical care
is too vague and could just as easily be applied to dispensing and as-
sociated clinical check services, as to more patient-centered activities.45
In some settings, clinical services such as ‘medicines management’, an
extension of pharmaceutical care, are considered by some to be
achievable with minimal patient information,46 a situation that would
lend itself to a more non-maleficent approach. Importantly, it could be
Fig. 2. A model for the clinical decision-making cycle for
non-maleficent pharmacy practice. The dashed line around
the decision component indicates that this is the final step in
process and will be enacted with the patient. The ‘decision’
component associated with the non-maleficent cycle concerns
the interaction with the primary beneficent practitioner.
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argued that in the absence of a fully developed range of clinical deci-
sion-making skills, those who practice pharmaceutical care might lack
requisite skills to extend beyond a non-maleficence (risk mitigation)
approach to practice.
There appears to be a general agreement amongst pharmacy edu-
cators, licensing bodies, and other stake-holders that the concept of
clinical decision-making is important in pharmacy practice and edu-
cation. Clinical decision-making is noted as a central component of
pharmacy competence in different jurisdictions47-50 and in standards of
practice documents.51-53 The skills of problem-solving, clinical rea-
soning, judgement, and decision-making are stressed in documentation
associated with schools of pharmacy, and accreditation standards for
education programmes.54-57 Yet, despite the importance of clinical de-
cision-making, pharmacists have been found to struggle with this in
practice.58 Pharmacists are said to feel inadequately prepared to make
important therapy decisions, are generally risk averse, and lack con-
fidence to deal with ambiguous situations.59 Recent work on the deci-
sion-making skills required for differential diagnosis in a community
pharmacy setting suggests that pharmacists rarely exhibit a robust de-
cision-making processes, relying instead on mnemonic or acronym-
based memory aids for assessing information from the patient and
making a decision.37,39 The reliance on mnemonics may imply that
pharmacists lack confidence when making independent decisions.38
There appears to be a gap between the aspirations of the pharmacy
profession and the current skill-base available to pharmacists in
practice. This gap is reflected in patient care settings where pharmacists
have not traditionally been primary decision makers. There is, there-
fore, an urgent need for the pharmacy education community to explore
purpose-built curriculum and new teaching methods that can support
the development of clinical decision-making skills across practice set-
tings. A critical part of this process is the need to provide support to
practitioners who wish to expand their practice into new roles. These
updates will ensure that the educators can keep pace with the changing
needs of the pharmacy profesison in the 12st century.
To support the continued evolution of clinical services in the
pharmacy profession we require further research and innovation in our
educational programs. We need to better understand how a seemingly
risk-averse culture of pharmacy practice has an impact on the curri-
culum in education programs. We also need to evaluate instructional
approaches that are designed to develop effective decision-making
skills in different practice settings, including the usefulness of the
proposed model for clinical decision-making presented in this paper.
We have presented a model for decision-making in pharmacy that
aligns with a philosophical framework for the profession. The model
has utility in undergraduate and postgraduate education programs for
pharmacists and as a basis for understanding clinical services in current
practice. We have suggested that for pharmacy to fully mature as a
clinical profession across practice settings, it is time to consider an
expanded professional identify accompanied by a formal process of
clinical decision-making for pharmacy.
Fig. 3. A model for the clinical decision-making cycle for secondary beneficent pharmacy practice, and the interaction with a primary beneficent practitioner. The
dashed line around the decision component indicates that this is the final step in process and will be enacted with the patient.
Fig. 4. A model for the clinical decision-making cycle for co-beneficent practice. The dashed line around the decision component indicates a collaborative decision.
This is the final step in process and will be enacted with the patient.
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